Mangoceuticals (MGRX) has entered into a Master Distribution Agreement to secure the exclusive licensing and distribution rights for Diabetinol within the United States and Canada. Diabetinol is a plant-based nutraceutical clinically supported and patented extract of citrus peel rich in polymethoxylated flavones, including nobiletin and tangeretin. Based on clinical studies performed, these compounds have demonstrated significant metabolic effects, particularly in how the body processes and utilizes sugar and fat. Mechanistically, Diabetinol works by improving insulin sensitivity, enhancing GLUT4-mediated glucose uptake in tissues, suppressing hepatic glucose production, and activating key enzymes involved in lipid metabolism. It also reduces systemic inflammation and oxidative stress-two of the primary biological drivers of insulin resistance and metabolic dysfunction. Under the agreement, Mangoceuticals will hold the exclusive rights to market and sell Diabetinol across the United States and Canada. Mangoceuticals intends to distribute Diabetinol in multiple consumer-friendly formats including capsules, a ready-to-drink beverage, quick-release pouches, cookies, and gummies. Each product will be carefully dosed to deliver consistent clinical levels of Diabetinol’s active ingredients. Distribution is expected to include direct-to-consumer online initiatives via our own website and through online retailers, brick and mortar retail outlets, and affiliate marketing channels.